Publications by authors named "Ryan Mattison"

Introduction: Obinutuzumab is hypothesized to improve progression-free survival (PFS) combined with bendamustine induction in mantle cell lymphoma (MCL). Measurable-residual disease (MRD) testing may predict benefit from maintenance therapy.

Methods: Adults (≥ 18 years) with untreated MCL ineligible for intensive therapies received 4 to 6 cycles of bendamustine + obinutuzumab (BO) followed by consolidation obinutuzumab (CO).

View Article and Find Full Text PDF
Article Synopsis
  • - The NCCN Guidelines for acute lymphoblastic leukemia (ALL) offer management recommendations that prioritize classifying ALL subtypes using immunophenotype and cytogenetic/molecular markers.
  • - The guidelines emphasize risk assessment and stratification to tailor therapy for both Ph-positive and Ph-negative ALL, specifically addressing treatment for adolescent, young adult, and adult patients.
  • - This excerpt highlights treatment recommendations specifically for adults newly diagnosed with Ph-negative ALL, grounded in the latest evidence-based research.
View Article and Find Full Text PDF

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T cell product generated from healthy donor T cells. WU-CART-007 was evaluated in a phase 1/2 study with a 3 + 3 dose-escalation design followed by cohort expansion in relapsed/refractory T-ALL/LBL.

View Article and Find Full Text PDF

Background: Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)-negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, may have efficacy in patients with MRD-negative remission.

Methods: In a phase 3 trial, we randomly assigned patients 30 to 70 years of age with -negative BCP-ALL (with :: indicating fusion) who had MRD-negative remission (defined as <0.

View Article and Find Full Text PDF

Purpose: Knowledge of an inherited predisposition to myelodysplastic syndrome (MDS) and AML has important clinical implications for treatment decisions, surveillance, and care of at-risk relatives. National Comprehensive Cancer Network (NCCN) guidelines recently incorporated recommendations for germline genetic evaluation of patients with MDS/AML on the basis of personal and family history features, but the practicality of implementing these recommendations has not been studied.

Methods: A hereditary hematology quality improvement (QI) committee was formed to implement these guidelines in a prospective cohort of patients diagnosed with MDS/AML.

View Article and Find Full Text PDF
Article Synopsis
  • The phase 3b FREEDOM trial tested the drug fedratinib's effectiveness and safety in patients with intermediate or high-risk myelofibrosis who had low platelet counts and were previously treated with ruxolitinib.
  • Despite being cut short due to COVID-19, 38 patients were enrolled, and in the final efficacy analysis, 25.7% achieved the primary goal of spleen volume reduction, while 62.9% had the best overall response leading to symptom improvement.
  • The study found that fedratinib led to significant clinical responses with fewer gastrointestinal side effects compared to previous trials, and there were no cases of encephalopathy among participants.
View Article and Find Full Text PDF

Purpose: Salivary dysfunction is a significant side effect of radiation therapy for head and neck cancer (HNC). Preliminary data suggests that mesenchymal stromal cells (MSCs) can improve salivary function. Whether MSCs from HNC patients who have completed chemoradiation are functionally similar to those from healthy patients is unknown.

View Article and Find Full Text PDF

Background Aims: Xerostomia, or the feeling of dry mouth, is a significant side effect of radiation therapy for patients with head and neck cancer (HNC). Preliminary data suggest that mesenchymal stromal/stem cells (MSCs) can improve salivary function. We performed a first-in-human pilot study of interferon gamma (IFNγ)-stimulated autologous bone marrow-derived MSCs, or MSC(M), for the treatment of radiation-induced xerostomia (RIX).

View Article and Find Full Text PDF

Next-generation sequencing (NGS) is important for prognostication and determining eligibility for targeted therapies in acute myeloid leukemia (AML). The use of NGS has increased in clinical practice, but variability in testing patterns still exist. The purpose of this study was to assess trends in molecular genetic sequencing in AML based on insurance status and area deprivation index (ADI), a validated metric of neighborhood disadvantage.

View Article and Find Full Text PDF
Article Synopsis
  • MRI is a key tool for measuring liver iron concentration (LIC), and this study compares the reproducibility of LIC estimation using R2* MRI versus R2 MRI across different MRI scanner vendors and strengths.
  • The research involved 207 participants across four medical centers and found a strong linear relationship between R2* values and LIC, confirming high reproducibility in measurements without significant differences among centers.
  • Calibration equations for LIC at various magnetic field strengths were developed, helping establish standardized methods for detecting liver iron overload through R2* MRI.
View Article and Find Full Text PDF

Background: Xerostomia, or dry mouth, is a common side effect of head and neck radiation. Current treatment options for radiation-induced xerostomia are generally supportive in nature. Adult stem cells are the ultimate source for replenishment of salivary gland tissue.

View Article and Find Full Text PDF

Recurrently mutated genes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have proven useful in risk stratification and clinical decision-making. Sequencing technologies that detect these genetic mutations are now widely available, though there is variability in the use of such data among hematologists. Molecular genetic sequencing trends were assessed in 470 patients presenting to a single institution with AML or MDS to determine how molecular data impacts clinical management of patients with myeloid malignancies.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and effectiveness of talazoparib for treating patients with advanced blood cancers.
  • - In a Phase I trial with 33 patients split into two cohorts, they found that the MTD was 2.0 mg/day for acute myeloid leukemia/myelodysplastic syndrome and 0.9 mg/day for chronic lymphocytic leukemia/mantle cell lymphoma, with over half of the participants having stable disease.
  • - The results indicated that talazoparib is generally well tolerated and demonstrates some early signs of anti-leukemic activity, comparable to its use in solid tumors.
View Article and Find Full Text PDF

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

View Article and Find Full Text PDF

Post-remission strategies after dasatinib-corticosteroid induction in adult Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) are not well studied. We evaluated dasatinib and dexamethasone induction then protocol-defined post-remission therapies, including hematopoietic cell transplantation (HCT). Adults (N = 65) with Ph-positive ALL received dasatinib-dexamethasone induction, methotrexate-based central nervous system (CNS) prophylaxis, reduced-intensity conditioning (RIC) allogeneic HCT, autologous HCT, or chemotherapy alone, and dasatinib-based maintenance.

View Article and Find Full Text PDF

Patients undergoing surgical procedures are one of the few populations that still require substantial doses of opioid medications to provide analgesia, despite the best efforts of clinicians to integrate non-opioid adjunctive analgesics into practice. While many options exist with varying degrees of evidence, one drug class that deserves renewed consideration are muscle relaxants. Although these medications have differing mechanisms of action and require a more thorough evaluation of patient parameters prior to administration as opposed to other adjunctive analgesics, it is readily apparent by the results of this review that these agents may be able to mitigate pain and limit opioid usage.

View Article and Find Full Text PDF

Safety and efficacy of allogeneic hematopoietic stem cell transplantation (alloHCT) consolidation after blinatumomab is largely undetermined. To address this issue, we assembled multi-center data of relapsed refractory (RR) acute lymphocytic leukemia (ALL) patients who received alloHCT after blinatumomab. From December 2014 to May 2019, 223 patients who received blinatumomab for RR ALL outside clinical trials were identified.

View Article and Find Full Text PDF

Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-X/BCL2 inhibitor, may allow targeting of both BCL2 and BCL-X without dose-limiting thrombocytopenia associated with navitoclax monotherapy. The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase I dose-escalation study (NCT03181126) in pediatric and adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia or lymphoblastic lymphoma. Forty-seven patients received treatment.

View Article and Find Full Text PDF

Purpose: Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin.

Methods: In a phase III, US intergroup trial, we randomly assigned patients to receive either LEN and EPO alfa or LEN alone following stratification by serum erythropoietin concentration and prior erythropoietin treatment.

View Article and Find Full Text PDF

Background: The availability of novel agents (NAs), including blinatumomab and inotuzumab ozogamicin (InO), has improved the outcomes of patients with relapsed/refractory (RR) B-cell acute lymphoblastic leukemia (ALL). Because of the relative effectiveness, it is often a challenge for clinicians to determine how to best sequence these NAs with respect to efficacy and toxicity.

Methods: In this multicenter, retrospective study of patients with RR ALL treated with blinatumomab, InO, or both, their efficacy as a first or second NA was compared.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: 8192

Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated

Filename: helpers/my_audit_helper.php

Line Number: 8900

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace

File: /var/www/html/application/controllers/Author.php
Line: 786
Function: formatAIDetailSummary

File: /var/www/html/application/controllers/Author.php
Line: 685
Function: pubMedSearchtoAuthorResults_array

File: /var/www/html/application/controllers/Author.php
Line: 122
Function: pubMedAuthorSearch_array

File: /var/www/html/index.php
Line: 316
Function: require_once